James Engelhart Biography and Net Worth

CFO of Biohaven

James Engelhart serves as Chief Financial Officer, Treasurer of Biohaven Pharmaceutical Holding Company Limited. Prior to this, from August 2014 to May 2016, he served as executive director of finance, Americas for Alexion Pharmaceuticals, Inc., and from March 2006 to July 2014, he served as a finance director for Energizer Holdings, Inc. From May 1998 to March 2006, Mr. Engelhart served in increasingly senior finance roles for BMS and held finance roles in R&D Operations and International Operations at Schering-Plough from 1992 to 1998. Mr. Engelhart currently serves on the board of directors of OLM School of Madison. Mr. Engelhart started his career as an auditor with Coopers & Lybrand LLP from 1986 through 1991. Mr. Engelhart received his B.S. in accounting from Villanova University and is a CPA (inactive).

What is James Engelhart's net worth?: The estimated net worth of James Engelhart is at least $821,115.00 as of June 11th, 2020. Mr. Engelhart owns 15,975 shares of Biohaven stock worth more than $821,115 as of November 5th. This net worth estimate does not reflect any other investments that Mr. Engelhart may own. Learn More about James Engelhart's net worth.
How do I contact James Engelhart?: The corporate mailing address for Mr. Engelhart and other Biohaven executives is 215 CHURCH STREET, NEW HAVEN CT, 06510. Biohaven can also be reached via phone at 203-404-0410 and via email at [email protected]. Learn More on James Engelhart's contact information.
Has James Engelhart been buying or selling shares of Biohaven?: James Engelhart has not been actively trading shares of Biohaven in the last ninety days. Most recently, James Engelhart sold 35,000 shares of the business's stock in a transaction on Friday, December 10th. The shares were sold at an average price of $102.55, for a transaction totalling $3,589,250.00. Learn More on James Engelhart's trading history.
Who are Biohaven's active insiders?: Biohaven's insider roster includes Irina Antonijevic (Director), Gregory Bailey (Director), Robert Berman (Insider), Matthew Buten (CFO), John Childs (Director), George Clark (CAO), Vlad Coric (CEO), Declan Doogan (Director), James Engelhart (CFO), Kimberly Gentile (SVP), Julia Gregory (Director), William Jones, Jr. (Insider), Elyse Stock (Insider), and John Tilton (Insider). Learn More on Biohaven's active insiders.
Are insiders buying or selling shares of Biohaven?: In the last twelve months, Biohaven insiders bought shares 8 times. They purchased a total of 307,186 shares worth more than $12,231,711.54. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 11,000 shares worth more than $459,690.00. The most recent insider tranaction occured on October, 2nd when Director John W Childs bought 21,052 shares worth more than $999,970.00. Insiders at Biohaven own 16.0% of the company. Learn More about insider trades at Biohaven.
Information on this page was last updated on 10/2/2024.

James Engelhart Insider Trading History at Biohaven

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2021	Sell	35,000	$102.55	$3,589,250.00
6/11/2020	Sell	73,725	$66.00	$4,865,850.00	15,975
6/27/2019	Buy	2,500	$43.05	$107,625.00
5/30/2018	Sell	5,000	$35.00	$175,000.00	5,000
5/7/2018	Sell	2,500	$27.67	$69,175.00
2/21/2018	Sell	538	$29.60	$15,924.80	3,038
1/22/2018	Sell	10,000	$32.50	$325,000.00	13,576
11/10/2017	Sell	30,538	$26.58	$811,700.04	25,176
5/9/2017	Buy	2,500	$17.00	$42,500.00	3,576

James Engelhart Buying and Selling Activity at Biohaven

Biohaven Company Overview

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $51.40

$49.48

$51.41

50 Day Range

MA: $46.04

$35.72

$53.73

2 Week Range

Now: $51.40

$26.80

$62.21

Volume

492,722 shs

Average Volume

1,148,214 shs

Market Capitalization

$4.86 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

A new way to play the AI boom (act before November 19)

From Behind the Markets | Ad

There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as little as $16 and a brokerage account.

Click here to get the ticker >>>